Risk Reduction clinical trials

Explore recruiting risk reduction clinical trials.

Recruiting risk reduction studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Risk Reduction trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY TM Study)

Poland, Romania, Belgium, Finland, Germany, Croatia +16 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, placebo controlled, observer-blind, phase IV pragmatic trial to evaluate the effect of Recombinant Zoster Vaccine (Shingrix®) on incident dementia diagnosis in an older adult population aged ≥76 years in Finland

Finland

Therapeutic use (Phase IV) EU CTIS Study details

A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis

Greece, Hungary, Italy, Spain, France, Bulgaria +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia

Belgium, France

Therapeutic use (Phase IV) EU CTIS Study details

A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis

Hungary, Poland, Belgium, Italy, Denmark, Portugal +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Risk Reduction trials by city

Risk Reduction in Toronto Risk Reduction in Vancouver Risk Reduction in Montreal Risk Reduction in Calgary Risk Reduction in Edmonton Risk Reduction in Ottawa Risk Reduction in Winnipeg Risk Reduction in Quebec City Risk Reduction in Hamilton Risk Reduction in Kitchener Risk Reduction in London Risk Reduction in Halifax Risk Reduction in New York Risk Reduction in Los Angeles Risk Reduction in Chicago Risk Reduction in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease